Gene · 111
ADCY5: adenylate cyclase 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADCY5: adenylate cyclase 5. Genes, record 111. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/111
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O95622 | Adenylate cyclase type 5 | 1,261 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents20
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 36696 | O95622 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 16748 | O95622 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 290 | O95622 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 290 | O95622 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 16748 | O95622 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 2814 | O95622 | Espacenet |
| EP 4220176 A2 | 2023-08-02 | 22 | O95622 | Espacenet |
| JP 2022160535 A | 2022-10-19 | 22 | O95622 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 2814 | O95622 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 6706 | O95622 | Espacenet |
1 to 10 of 20
See all 20 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,531
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADCY5 papers | Newest fiscal year |
|---|---|---|---|
| ZIAHG000024 | Genetic analysis of type II diabetes | 16 | 2025 |
| R01DK062370 | Identifying Genes for Type 2 Diabetes: FUSION | 13 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 12 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 10 | 2025 |
| R01DK093757 | Genetic epidemiology of rare and regulatory variants for metabolic traits | 10 | 2025 |
| R01HL086694 | From GWAS loci to blood pressure genes, variants & mechanisms - Renewal | 8 | 2025 |
| ZIADA000493 | Functional and Pharmacological Significance of Receptor Heteromers in the CNS | 8 | 2025 |
| UL1TR001881 | UCLA Clinical and Translational Science Institute | 5 | 2025 |
| P20GM109036 | Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases | 4 | 2025 |
| R01DK075787 | Biological Insights from Genetic Investigation of ANthropometric Traits (GIANT) Across the Allelic Spectrum | 4 | 2025 |
1 to 10 of 1,531Source NIH's project files
See all 1,531 nih grantsPapers1,453
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| High-throughput phenotypic screening identifies the phytochemical melissic acid that mitigates SHED cellular senescence via the ADCY5/cAMP/CREB axis. | Front Pharmacol | 2026 | 42824422 | PubTator, text mining | PubMed |
| Adenylyl cyclase 9 as a molecular scaffold to dissect the mechanisms of membrane adenylyl cyclases. | Protein Sci | 2026 | 42752937 | PubTator, text mining | PubMed |
| Novel and Emerging Therapies for Childhood-Onset Movement Disorders. | Mov Disord | 2026 | 42723627 | PubTator, text mining | PubMed |
| Annexin A4 Deficient Ventricular Myocytes Display Advanced Hypertrophy and Electrical Remodeling With Chronic β-Adrenoceptor Stimulation. | FASEB J | 2026 | 42684683 | PubTator, text mining | PubMed |
| Phylogeographic Structure and Molecular Evolution of Squash Leaf Curl China Virus. | Viruses | 2026 | 42515646 | PubTator, text mining | PubMed |
| Relative Efficacy of Self-Managed Caffeine Supplementation in Maintaining Daily Activity in a Patient with ADCY5-Related Dyskinesia: A Case Report. | Case Rep Neurol | 2026 | 42422538 | PubTator, text mining | PubMed |
| ADCY2, ADCY5, and GRIA1 as key genes of the cAMP signaling pathway in osteoporotic spinal fracture after manipulation of Wnt signaling. | Arch Med Sci | 2026 | 42305321 | PubTator, text mining | PubMed |
| Maternal Genetic Variants and Gestational Duration: A Replication Study in a Japanese Cohort. | J Clin Med | 2026 | 42279130 | PubTator, text mining | PubMed |
| Parkinsonism in Childhood, a Clue to Autosomal Recessive ADCY5-Related Movement Disorder? | Mov Disord Clin Pract | 2026 | 42120309 | PubTator, text mining | PubMed |
| Distinct Brain Drivers and Shared Cerebello-Cortical Input in ADCY5 and SGCE Hyperkinetic Movements. | Mov Disord | 2026 | 42063207 | PubTator, text mining | PubMed |
1 to 10 of 1,453
See all 1,453 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/111
GET https://conductscience.org/api/genes/v1/111/patents